UMMC Navigation

Cancer

Main Content

AALL1621

Study title

Phase 2 study of inotuzumab ozogamicin in children and young adults with relapsed or refractory cd22+b acute lymphoblastic leukemia

  • Principal Investigator: Dr. Anderson Collier

Purpose

This study is looking at the effects of an experimental drug in pediatric patients with relapsed leukemia.

Who can participate

Those eligible to participate in this study include:
  • Children, adolescents, and young adults between the ages of 1-21 who have relapsed leukemia

For more information

  • Julie Hornaday, RN
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson, MS 39216
    (601) 984-2712
  • IRB Number: 2017-0198